PARPi: Management of Adverse Events Webcast (2024)

The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered. The first in the series, PARPi: Precision Medicine in Advanced Prostate Cancer features a multidisciplinary panel, including a urologist, oncologist, and APP, to present the latest advances in PARPi. The expert faculty will engage in an interactive, case-based discussion amongst each other and engage with the learners through Q&A.


This educational activity is supported by an independent educational grant from:

  • Pfizer, Inc.

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners, Physician Assistants, Nurse Navigators)

Learning Objectives

At the conclusion of this activity, the learner will be able to:

  1. Identify approved PARPi for prostate cancer and patients who may benefit from PARPi based therapy.
  2. Evaluate available clinical safety and efficacy data for PARPi.
  3. Describe indications and contraindications for PARPi in patients with advanced prostate cancer.
  4. Identify how to manage adverse events that patients may experience while taking a PARPi.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Morgans, AliciaBayerConsultant or AdvisorCurrent
Morgans, AliciaAstra ZenecaConsultant or AdvisorCurrent
Morgans, AliciaAstellasConsultant or AdvisorCurrent
Morgans, AliciaSanofiConsultant or AdvisorCurrent
Morgans, AliciaJanssenConsultant or AdvisorCurrent
Morgans, AliciaDendreonConsultant or AdvisorCurrent
Morgans, AliciaMerckConsultant or AdvisorCurrent
Morgans, AliciaBMSConsultant or AdvisorCurrent
Morgans, AliciaPfizerConsultant or AdvisorCurrent
Morgans, AliciaMyovantConsultant or AdvisorCurrent
Morgans, AliciaAdvanced Accelerator ApplicationsConsultant or AdvisorCurrent
Morgans, AliciaLantheusConsultant or AdvisorCurrent
Morgans, AliciaMyriadConsultant or AdvisorCurrent
Morgans, AliciaTelixConsultant or AdvisorCurrent
Morgans, AliciaNovartisConsultant or AdvisorCurrent
Morris, David ScottAstellasConsultant or AdvisorCurrent
Morris, David ScottJanssenConsultant or AdvisorCurrent
Morris, David ScottBayerConsultant or AdvisorCurrent
Morris, David ScottMyriadConsultant or AdvisorCurrent
Morris, David ScottClovisConsultant or Advisor12/01/2022
Morris, David ScottUroGen PharmaConsultant or AdvisorCurrent
Morris, David ScottAstraZenecaConsultant or AdvisorCurrent
Morris, David ScottMerckConsultant or AdvisorCurrent
Morris, David ScottInvitaeScientific Study or Trial12/31/2022
Morris, David ScottDecipher BioConsultant or AdvisorCurrent
Morris, David ScottTolmarConsultant or AdvisorCurrent
Morris, David ScottMyovantConsultant or AdvisorCurrent
Morris, David ScottProgenicsConsultant or Advisor02/07/2023
Morris, David ScottPfizerMeeting Participant or LecturerCurrent
Morris, David ScottLantheusConsultant or AdvisorCurrent
Morris, David ScottBlue Earth DiagnosticsConsultant or AdvisorCurrent
Ross, Ashley E.GenomeDx BiosciencesConsultant or AdvisorCurrent
Ross, Ashley E.JanssenConsultant or AdvisorCurrent
Ross, Ashley E.PfizerConsultant or AdvisorCurrent
Ross, Ashley E.Blue EarthConsultant or AdvisorCurrent
Ross, Ashley E.TEMPUSConsultant or AdvisorCurrent
Ross, Ashley E.BayerConsultant or AdvisorCurrent
Ross, Ashley E.MyovantConsultant or AdvisorCurrent
Ross, Ashley E.AstellasConsultant or AdvisorCurrent
Ross, Ashley E.VeracyteConsultant or AdvisorCurrent
Ross, Ashley E.LantheusConsultant or AdvisorCurrent


PDF icon Education Council Disclosures 2023.pdf


PDF icon COI Review Work Group Disclosures_2023.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.


Method of Participation: Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hours

Release Date: January, 2024
Expiration Date: January, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.